Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00934050
Other study ID # ELND005-AD251
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date June 2009
Est. completion date June 2011

Study information

Verified date October 2019
Source OPKO Health, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the long-term safety and tolerability of ELND005 beyond the 18 months of treatment in original randomized and blinded clinical trail ELND005-AD201.


Recruitment information / eligibility

Status Completed
Enrollment 103
Est. completion date June 2011
Est. primary completion date June 2011
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- This study is open only to subjects who have completed the week 78 visit in Study ELND005-AD201 while taking their assigned dose of study drug medication.

Exclusion Criteria:

- Subject has no new medical contraindications to continued participation in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ELND005 (scyllo-inositol)
Prior to 15Dec2009: ELND005 2000 mg PO BID for 48 weeks After 15Dec2009: ELND005 250 mg PO BID for 48 weeks

Locations

Country Name City State
Canada Glenrose Rehabilitation Hospital Edmonton Alberta
Canada Parkwood Hospital London Ontario
Canada Recherche Clinique de Neurologie (Hospital Maisonneuve Rosemont) Montreal Quebec
Canada Sisters of Charity of Ottawa Health Service Ottawa Ontario
Canada Kawartha Regional Memory Clinic Peterborough Ontario
Canada Gerontion Research, Inc. Toronto Ontario
Canada Whitby Mental Health Memory Clinic Toronto Ontario
Canada University of British Columbia Hospital, Division of Neurology Vancouver British Columbia
United States Neurological Associates of Albany, PC Albany New York
United States Albuquerque Neuroscience, Inc. Albuquerque New Mexico
United States Emory University, Dept. of Neurology Atlanta Georgia
United States Clinical Neuroscience Research Associates, Inc-The Memory Clinic Bennington Vermont
United States Dekalb Neurology Associates, LLC Decatur Georgia
United States Brain Matters Research Delray Beach Florida
United States Memory Enhancement Center of America, Inc. Eatontown New Jersey
United States Margolin Brain Institute Fresno California
United States Collaborative NeuroScience Network, Inc. Garden Grove California
United States Alliance for Neuro Research, LLC dba Absher Neurology, PA Greenville South Carolina
United States Sunrise Clinical Research, Inc Hollywood Florida
United States Department of Neurology - Indiana University Medical Center Indianapolis Indiana
United States The Clinical Trial Center, LLC Jenkintown Pennsylvania
United States University of Kansas Medical Center, Department of Neurology Kansas City Kansas
United States Medford Neurological and Spine Clinic Medford Oregon
United States Yale University School of Medicine, Alzheimer's Disease Research Unit New Haven Connecticut
United States Columbia University Sergievsky Center New York New York
United States Innovative Clinical Concepts Paducah Kentucky
United States Banner Alzheimer's Institute Phoenix Arizona
United States University of Pittsburgh Alzheimer Disease Research Clinic Pittsburgh Pennsylvania
United States Summit Research Newtwork, Inc. Portland Oregon
United States Global Medical Institutes Princeton New Jersey
United States Butler Hospital, Memory and Aging Center Providence Rhode Island
United States Raleigh Neurology Associates Raleigh North Carolina
United States AD-CARE, Monroe Community Hospital Rochester New York
United States Roskamp Institute Sarasota Florida
United States Sun Health Research Institute Sun City Arizona
United States Neurology & Neuroscience Center of Ohio Toledo Ohio
United States University of Arizona, Health Sciences Center, Dept. of Neurology Tucson Arizona
United States Premiere Research Institute West Palm Beach Florida

Sponsors (1)

Lead Sponsor Collaborator
OPKO Health, Inc.

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Treatment Emergent Adverse Events (TEAEs) Safety and Tolerability was assessed by the incidence of Treatment Emergent Adverse Events (TEAEs) 12 months
See also
  Status Clinical Trial Phase
Completed NCT05040048 - Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
Withdrawn NCT03316898 - A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease Phase 1
Withdrawn NCT02860065 - CPC-201 Alzheimer's Disease Type Dementia: PET Study Phase 2
Completed NCT01315639 - New Biomarker for Alzheimer's Disease Diagnostic N/A
Not yet recruiting NCT03740178 - Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005) Phase 1
Recruiting NCT05607615 - A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease Phase 2
Terminated NCT03307993 - Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease Phase 1
Recruiting NCT02912936 - A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease N/A
Active, not recruiting NCT02899091 - Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease Phase 1/Phase 2
Not yet recruiting NCT02868905 - Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women N/A
Completed NCT02907567 - Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease Phase 1/Phase 2
Terminated NCT02521558 - Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease N/A
Completed NCT02516046 - 18F-AV-1451 Autopsy Study Phase 3
Completed NCT02580305 - SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study Phase 2
Recruiting NCT02247180 - Cognitive Rehabilitation in Alzheimer`s Disease N/A
Terminated NCT02220738 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors Phase 1
Completed NCT02317523 - Alzheimer's Caregiver Coping: Mental and Physical Health N/A
Completed NCT02256306 - The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study N/A
Completed NCT02260167 - Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol N/A
Not yet recruiting NCT01940952 - Zydena on Cognitive Function of Alzheimer's Disease Patients Phase 3